Cooper Companies Inc (COO) reported better-than-expected financial results for the fourth quarter of fiscal 2025. The company's earnings per share (EPS) reached $1.15, surpassing Wall Street's consensus estimate of $1.12 by $0.03. Revenue remained steady at $1.1 billion, matching analyst expectations.
The earnings report highlights the company's operational performance and financial health amid a competitive landscape. Cooper Companies operates as a medical device company, employing 16,000 full-time staff across its two primary business units: CooperVision and CooperSurgical. The CooperVision segment specializes in the contact lens market, while CooperSurgical focuses on fertility and women's health care, offering a diverse range of products and services.
Cooper Companies will host its earnings conference call to discuss these results and provide further insights into its business performance. Investors are encouraged to review the full earnings release and management commentary for a comprehensive understanding of the quarter's performance and future outlook.
As of November 18, 2025, Cooper Companies has a market capitalization of $14.2 billion and a P/E ratio of 34.78. The company’s upcoming earnings reports are scheduled for March 4, 2026, with an EPS estimate of $1.02 and revenue expectation of $1.0 billion, followed by another report on May 27, 2026, with an EPS estimate of $1.06 and revenue of $1.1 billion.